The global pancreatic cancer market accounted for USD 2.57 billion in 2023 and is expected to reach USD 10.39 billion by 2034 with a CAGR of 13.56% during the forecast period 2024-2034. The market is going to grow as a result of factors such as the increasing prevalence of pancreatic cancer, rising treatment awareness, technological and scientific advancements in medicine, and strategic alliances and collaborations.
Diagnoses of pancreatic cancer are rising as a result of bad lifestyle choices and an aging population. Globally, the prevalence of risk factors like diabetes, obesity, and tobacco use is rising. Research organizations, biotechnology corporations, and pharmaceutical companies are working together more frequently to hasten the development and launching of pancreatic cancer treatments. For instance, AstraZeneca reported encouraging findings in December 2023 from the Phase III ELEVATE-RR study, which assessed the combination of its PARP inhibitor, Lynparza (olaparib), and bevacizumab for advanced pancreatic cancer.
By cancer type, the exocrine pancreatic cancer segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to the high prevalence of adenocarcinoma, which is the most common type of exocrine pancreatic cancer, coupled with advancements in treatment options and early detection techniques. For instance, Lilly announced good Phase III findings in January 2024 for bemarituzumab, an experimental medication used in combination with chemotherapy for patients with advanced pancreatic cancer. Additionally, the endocrine pancreatic cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, improved diagnostic techniques, and development of targeted therapies specifically tailored for pancreatic neuroendocrine tumors (PNETs), along with rising incidence rates globally.
By treatment type, the chemotherapy segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to its widespread adoption as a standard treatment option across all stages of the disease, supported by ongoing research and development efforts to enhance treatment efficacy and reduce side effects. For instance, Clovis Oncology stated in January 2024 that Phase I/II research of FAP-2286, an experimental drug, in combination with chemotherapy is being initiated for pancreatic cancer. Additionally, the targeted drug therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in precision medicine, increased understanding of molecular targets, and the development of novel targeted therapies tailored to specific genetic mutations associated with pancreatic cancer, offering improved efficacy and reduced toxicity compared to traditional chemotherapy.
By end-user, the hospital’s segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to its role as the primary setting for diagnosis, treatment, and management of pancreatic cancer patients, offering a wide range of services including surgery, chemotherapy, radiation therapy, and supportive care under one roof. For instance, Taiho Pharmaceutical reported encouraging outcomes from the Phase III TAS-118 trial, which assessed the efficacy of its oral fluoropyrimidine drug for metastatic pancreatic cancer, in September 2023. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to an increasing focus on personalized and specialized care for pancreatic cancer patients, offering advanced treatment modalities, multidisciplinary care teams, and patient-centric approaches that cater specifically to the complex needs of individuals with pancreatic cancer.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of advanced healthcare infrastructure, high adoption rates of novel therapies, strong research and development activities, favorable reimbursement policies, and a growing prevalence of pancreatic cancer in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to improving healthcare infrastructure, increasing awareness about pancreatic cancer, rising disposable income levels, expanding access to advanced diagnostic and treatment options, and a growing focus on research and development initiatives in the region. For instance, in November 2023, Eisai reported successful outcomes from a Phase Ib/II trial involving its experimental antibody-drug conjugate (ADC) treatment for advanced pancreatic cancer.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Diagnoses of pancreatic cancer are rising as a result of bad lifestyle choices and an aging population. Globally, the prevalence of risk factors like diabetes, obesity, and tobacco use is rising. Research organizations, biotechnology corporations, and pharmaceutical companies are working together more frequently to hasten the development and launching of pancreatic cancer treatments. For instance, AstraZeneca reported encouraging findings in December 2023 from the Phase III ELEVATE-RR study, which assessed the combination of its PARP inhibitor, Lynparza (olaparib), and bevacizumab for advanced pancreatic cancer.
By cancer type, the exocrine pancreatic cancer segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to the high prevalence of adenocarcinoma, which is the most common type of exocrine pancreatic cancer, coupled with advancements in treatment options and early detection techniques. For instance, Lilly announced good Phase III findings in January 2024 for bemarituzumab, an experimental medication used in combination with chemotherapy for patients with advanced pancreatic cancer. Additionally, the endocrine pancreatic cancer segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness, improved diagnostic techniques, and development of targeted therapies specifically tailored for pancreatic neuroendocrine tumors (PNETs), along with rising incidence rates globally.
By treatment type, the chemotherapy segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to its widespread adoption as a standard treatment option across all stages of the disease, supported by ongoing research and development efforts to enhance treatment efficacy and reduce side effects. For instance, Clovis Oncology stated in January 2024 that Phase I/II research of FAP-2286, an experimental drug, in combination with chemotherapy is being initiated for pancreatic cancer. Additionally, the targeted drug therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the advancements in precision medicine, increased understanding of molecular targets, and the development of novel targeted therapies tailored to specific genetic mutations associated with pancreatic cancer, offering improved efficacy and reduced toxicity compared to traditional chemotherapy.
By end-user, the hospital’s segment accounted for the highest revenue-grossing segment in the global pancreatic cancer market in 2023 owing to its role as the primary setting for diagnosis, treatment, and management of pancreatic cancer patients, offering a wide range of services including surgery, chemotherapy, radiation therapy, and supportive care under one roof. For instance, Taiho Pharmaceutical reported encouraging outcomes from the Phase III TAS-118 trial, which assessed the efficacy of its oral fluoropyrimidine drug for metastatic pancreatic cancer, in September 2023. Additionally, the specialty clinics segment is predicted to grow at the fastest CAGR during the forecast period owing to an increasing focus on personalized and specialized care for pancreatic cancer patients, offering advanced treatment modalities, multidisciplinary care teams, and patient-centric approaches that cater specifically to the complex needs of individuals with pancreatic cancer.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of advanced healthcare infrastructure, high adoption rates of novel therapies, strong research and development activities, favorable reimbursement policies, and a growing prevalence of pancreatic cancer in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to improving healthcare infrastructure, increasing awareness about pancreatic cancer, rising disposable income levels, expanding access to advanced diagnostic and treatment options, and a growing focus on research and development initiatives in the region. For instance, in November 2023, Eisai reported successful outcomes from a Phase Ib/II trial involving its experimental antibody-drug conjugate (ADC) treatment for advanced pancreatic cancer.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Cancer Type, Treatment Type, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Pancreatic Cancer Market Report 2023 - 2034
Pancreatic Cancer Market Analysis & Forecast by Cancer Type 2023 - 2034 (Revenue USD Bn)
- Endocrine Pancreatic Cancer
- Exocrine Pancreatic Cancer
Pancreatic Cancer Market Analysis & Forecast by Treatment Type 2023 - 2034 (Revenue USD Bn)
- Chemotherapy
- Immunotherapy
- Hormone Therapy
- Surgery
- Radiation Therapy
- Targeted Drug Therapy
- Others
Pancreatic Cancer Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinics
- Diagnostic Laboratories
- Research Institutes
- Research Laboratories
- Others
Pancreatic Cancer Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Pancreatic Cancer Market: Cancer Type Estimates & Trend Analysis
8. Pancreatic Cancer Market: Treatment Type Estimates & Trend Analysis
9. Pancreatic Cancer Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Pancreatic Cancer Market
12. Europe Global Pancreatic Cancer Market
13. Asia Pacific Global Pancreatic Cancer Market
14. Latin America Global Pancreatic Cancer Market
15. MEA Global Pancreatic Cancer Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- AstraZeneca
- Celgene Corporation
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- AbbVie Inc.
- Clovis Oncology
- Ipsen Pharma
- Taiho Pharmaceutical Co. Ltd.
- Halozyme Therapeutics Inc.
- Shire
- OncoGenex Pharmaceuticals Inc.
- Eisai Co. Ltd.
